Brain Cancer Clinical Trials in Nashville

Showing 81-100 of 178 trials

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

NCT02386826

The purpose of this study is to determine whether the combination of two agents, INC280 and bevacizumab, is safe and effective when administered to patients with Glioblastoma Multiforme (GBM) who have progressed after receiving prior therapy or who have unresectable GBM.

Glioblastoma MultiformeGliosarcomaColorectal Cancer+1 more

SCRI Development Innovations, LLC65 participantsStarted Sep 2015

Denver, Colorado, United States • New Haven, Connecticut, United States • Kansas City, Missouri, United States +2 more locations

COMPLETEDPhase 3< 1 mile

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

NCT02617589

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-unmethylated (the MGMT gene is not altered by a chemical change). Patients will receive Nivolumab every two weeks in addition to radiation therapy, and then every four weeks. They will be compared to patients receiving standard therapy with temozolomide in addition to radiation therapy.

Brain Cancer

Bristol-Myers Squibb560 participantsStarted Mar 2016

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +122 more locations

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Brain Cancer Trials in Other Cities

Expanded Access Protocol Using 131I-MIBG

Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

3D Prediction of Patient-Specific Response

Evaluation of GLR2007 for Advanced Solid Tumors

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Other Conditions in Nashville